Communicating scientific evidence: drugs for Alzheimer's disease as a case study

Current Medical Research and Opinion, Год журнала: 2025, Номер unknown, С. 1 - 15

Опубликована: Янв. 24, 2025

This paper reviews the scientific evidence on new anti-amyloid monoclonal antibodies for treating Alzheimer's disease as a case study improving communication. We introduce five guidelines condensed from biomedical literature but adapted to short format of science communication in e.g., journal opinion pieces and newspaper articles. Given major importance recent confusion regarding discussed drugs, with certain disagreements seen between FDA EMA, suggested may be useful clinicians discussing their patients scientists communicating balance. More generally, we hope that help us improve complex topics literature, advocacy, media appearances.

Язык: Английский

---

Real-world datasets for the International Registry for Alzheimer's Disease and Other Dementias (InRAD) and other registries: An international consensus

The Journal of Prevention of Alzheimer s Disease, Год журнала: 2025, Номер unknown, С. 100096 - 100096

Опубликована: Фев. 1, 2025

Many dementia and Alzheimer's disease (AD) registries operate at local or national levels without standardization comprehensive real-world data (RWD) collection. This initiative sought to achieve consensus among experts on priority outcomes measures for clinical practice in caring patients with symptomatic AD, particularly the mild cognitive impairment moderate stages. The primary aim was define a minimum dataset (MDS) extended (EDS) collect RWD new International Registry AD Other Dementias (InRAD) other registries. MDS EDS focus informing routine practice, covering relevant comorbidities safety, are designed be easily integrated into existing capture systems. An international steering committee (ISC) of clinician lead initiative. first drafts were developed based previous global inter-societal Delphi outcome AD. Based ISC discussions, survey devised sent wider stakeholder group. discussed results, resulting covering: patient profile demographics; lifestyle anthropometrics; co-morbidities diagnostics; imaging; treatment; characterization; safety; discontinuation; laboratory tests; care partner outcomes; interface functionality. By learning from successful examples areas, addressing current limitations, proactively enhancing quality analytical rigor, InRAD registry will foundation contribute improving neurodegenerative diseases.

Язык: Английский

---

Evaluating Lecanemab Eligibility for Patients in Skilled Nursing Facilities With Alzheimer Disease or Mild Cognitive Impairment

Journal of the American Medical Directors Association, Год журнала: 2024, Номер 25(11), С. 105192 - 105192

Опубликована: Авг. 6, 2024

Язык: Английский

---

Application of mitochondrial miRNA-204 nanoprobes in Alzheimer's disease treatment by clearing reactive oxygen species-mediated autophagy

Chinese Chemical Letters, Год журнала: 2024, Номер unknown, С. 110614 - 110614

Опубликована: Ноя. 1, 2024

Язык: Английский

---

The Effect of Tablet-Based Digital Cognitive Training Program for Older Adults in Japan: A Pilot Study

Journal of Cognitive Intervention and Digital Health, Год журнала: 2024, Номер 3(1), С. 19 - 19

Опубликована: Янв. 1, 2024

Язык: Английский

---